ID   DCUP_HUMAN              Reviewed;         367 AA.
AC   P06132; A8K762; Q16863; Q16883; Q53YB8; Q53ZP6; Q6IB28; Q9BUZ0;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   10-MAY-2017, entry version 197.
DE   RecName: Full=Uroporphyrinogen decarboxylase;
DE            Short=UPD;
DE            Short=URO-D;
DE            EC=4.1.1.37;
GN   Name=UROD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 2-21; 37-65;
RP   101-123; 175-251; 259-322; 325-344 AND 346-367.
RX   PubMed=3015909;
RA   Romeo P.-H., Raich N., Dubart A., Beaupain D., Pryor M., Kushner J.P.,
RA   Cohen-Solal M., Goossens M.;
RT   "Molecular cloning and nucleotide sequence of a complete human
RT   uroporphyrinogen decarboxylase cDNA.";
RL   J. Biol. Chem. 261:9825-9831(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HEP LEU-62; LEU-77;
RP   GLU-281 AND CYS-311.
RX   PubMed=8644733;
RA   Moran-Jimenez M.J., Ged C., Romana M., de Salamanca R.E., Taieb A.,
RA   Topi G., D'Alessandro L., de Verneuil H.;
RT   "Uroporphyrinogen decarboxylase: complete human gene sequence and
RT   molecular study of three families with hepatoerythropoietic
RT   porphyria.";
RL   Am. J. Hum. Genet. 58:712-721(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Mendez M.;
RL   Submitted (FEB-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LEU-77.
RA   Martinez di Montemuros F., Fiorelli G., Cappellini M.D.;
RT   "Uroporphyrinogen decarboxylase (UROD) cDNA sequence from Italian
RT   population.";
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-77.
RA   Martinez di Montemuros F., Cappellini M.D.;
RT   "Molecular characterization of UROD gene in Italian patients with
RT   familial porphyria cutanea tarda (f-PCT).";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-303.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skeletal muscle;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-303.
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-7.
RX   PubMed=3658695; DOI=10.1093/nar/15.18.7343;
RA   Romana M., Dubart A., Beaupain D., Chabret C., Goossens M.,
RA   Romeo P.-H.;
RT   "Structure of the gene for human uroporphyrinogen decarboxylase.";
RL   Nucleic Acids Res. 15:7343-7356(1987).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 95-258, AND INVOLVEMENT IN FPCT.
RX   PubMed=2243121; DOI=10.1172/JCI114856;
RA   Garey J.R., Harrison L.M., Franklin K.F., Metcalf K.M., Radisky E.S.,
RA   Kushner J.P.;
RT   "Uroporphyrinogen decarboxylase: a splice site mutation causes the
RT   deletion of exon 6 in multiple families with porphyria cutanea
RT   tarda.";
RL   J. Clin. Invest. 86:1416-1422(1990).
RN   [15]
RP   CRYSTALLIZATION, IDENTIFICATION BY MASS SPECTROMETRY, AND SUBUNIT.
RX   PubMed=9194196; DOI=10.1002/pro.5560060624;
RA   Phillips J.D., Whitby F.G., Kushner J.P., Hill C.P.;
RT   "Characterization and crystallization of human uroporphyrinogen
RT   decarboxylase.";
RL   Protein Sci. 6:1343-1346(1997).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS), AND SUBUNIT.
RX   PubMed=9564029; DOI=10.1093/emboj/17.9.2463;
RA   Whitby F.G., Phillips J.D., Kushner J.P., Hill C.P.;
RT   "Crystal structure of human uroporphyrinogen decarboxylase.";
RL   EMBO J. 17:2463-2471(1998).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF VARIANTS FPCT ASP-156;
RP   LEU-232 AND THR-260, VARIANTS FPCT GLU-25; SER-80; GLN-134; ASP-156;
RP   ARG-165; LYS-167; PRO-193; LEU-232; GLN-253 AND THR-260, AND
RP   CHARACTERIZATION OF VARIANTS FPCT GLU-25; SER-80; GLN-134; ASP-156;
RP   ARG-165; LYS-167; PRO-193; LEU-232; GLN-253 AND THR-260.
RX   PubMed=11719352; DOI=10.1182/blood.V98.12.3179;
RA   Phillips J.D., Parker T.L., Schubert H.L., Whitby F.G., Hill C.P.,
RA   Kushner J.P.;
RT   "Functional consequences of naturally occurring mutations in human
RT   uroporphyrinogen decarboxylase.";
RL   Blood 98:3179-3185(2001).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF WILD-TYPE AND MUTANTS
RP   ASN-86; GLU-86; GLY-86 AND PHE-164 IN COMPLEX WITH SUBSTRATE ANALOGS,
RP   MUTAGENESIS OF ASP-86 AND TYR-164, AND REACTION MECHANISM.
RX   PubMed=14633982; DOI=10.1093/emboj/cdg606;
RA   Phillips J.D., Whitby F.G., Kushner J.P., Hill C.P.;
RT   "Structural basis for tetrapyrrole coordination by uroporphyrinogen
RT   decarboxylase.";
RL   EMBO J. 22:6225-6233(2003).
RN   [23]
RP   VARIANT HEP GLU-281.
RX   PubMed=3775362; DOI=10.1126/science.3775362;
RA   de Verneuil H., Grandchamp B., Beaumont C., Picat C., Nordmann Y.;
RT   "Uroporphyrinogen decarboxylase structural mutant (Gly-281-->Glu) in a
RT   case of porphyria.";
RL   Science 234:732-734(1986).
RN   [24]
RP   VARIANT FPCT VAL-281.
RX   PubMed=2920211;
RA   Garey J.R., Hansen J.L., Harrison L.M., Kennedy J.B., Kushner J.P.;
RT   "A point mutation in the coding region of uroporphyrinogen
RT   decarboxylase associated with familial porphyria cutanea tarda.";
RL   Blood 73:892-895(1989).
RN   [25]
RP   VARIANT HEP LYS-167.
RX   PubMed=1905636; DOI=10.1111/j.1365-2362.1991.tb01814.x;
RA   Romana M., Grandchamp B., Dubart A., Amselem S., Chabret C.,
RA   Nordmann Y., Goossens M., Romeo P.-H.;
RT   "Identification of a new mutation responsible for hepatoerythropoietic
RT   porphyria.";
RL   Eur. J. Clin. Invest. 21:225-229(1991).
RN   [26]
RP   VARIANT HEP GLY-292.
RX   PubMed=1634232;
RA   de Verneuil H., Bourgeois F., de Rooij F.W.M., Siersema P.D.,
RA   Wilson J.H.P., Grandchamp B., Nordmann Y.;
RT   "Characterization of a new mutation (R292G) and a deletion at the
RT   human uroporphyrinogen decarboxylase locus in two patients with
RT   hepatoerythropoietic porphyria.";
RL   Hum. Genet. 89:548-552(1992).
RN   [27]
RP   VARIANTS HEP GLN-134 AND PRO-220.
RX   PubMed=8176248; DOI=10.1111/1523-1747.ep12374134;
RA   Meguro K., Fujita H., Ishida N., Akagi R., Kurihara T.,
RA   Galbraith R.A., Kappas A., Zabriskie J.B., Toback A.C., Harber L.C.,
RA   Sassa S.;
RT   "Molecular defects of uroporphyrinogen decarboxylase in a patient with
RT   mild hepatoerythropoietic porphyria.";
RL   J. Invest. Dermatol. 102:681-685(1994).
RN   [28]
RP   VARIANT FPCT GLU-281.
RX   PubMed=7706766; DOI=10.1111/1523-1747.ep12605953;
RA   Roberts A.G., Elder G.H., de Salamanca R.E., Herrero C., Lecha M.,
RA   Mascaro J.M.;
RT   "A mutation 'G281E' of the human uroporphyrinogen decarboxylase gene
RT   causes both hepatoerythropoietic porphyria and overt familial
RT   porphyria cutanea tarda: biochemical and genetic studies on Spanish
RT   patients.";
RL   J. Invest. Dermatol. 104:500-502(1995).
RN   [29]
RP   VARIANT HEP GLY-80, AND VARIANTS FPCT GLN-253; ARG-318 AND THR-334.
RX   PubMed=8896428;
RA   McManus J.F., Begley C.G., Sassa S., Ratnaike S.;
RT   "Five new mutations in the uroporphyrinogen decarboxylase gene
RT   identified in families with cutaneous porphyria.";
RL   Blood 88:3589-3600(1996).
RN   [30]
RP   VARIANTS FPCT ARG-165; PHE-195; LYS-304 AND HIS-332.
RX   PubMed=9792863; DOI=10.1086/302119;
RA   Mendez M., Sorkin L., Rossetti M.V., Astrin K.H., Batlle A.M.C.,
RA   Parera V.E., Aizencang G.I., Desnick R.J.;
RT   "Familial porphyria cutanea tarda: characterization of seven novel
RT   uroporphyrinogen decarboxylase mutations and frequency of common
RT   hemochromatosis alleles.";
RL   Am. J. Hum. Genet. 63:1363-1375(1998).
RN   [31]
RP   VARIANT FPCT GLN-134.
RX   PubMed=10338097;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<412::AID-HUMU11>3.3.CO;2-K;
RA   McManus J.F., Begley C.G., Sassa S., Ratnaike S.;
RT   "Three new mutations in the uroporphyrinogen decarboxylase gene in
RT   familial porphyria cutanea tarda.";
RL   Hum. Mutat. 13:412-412(1999).
RN   [32]
RP   VARIANTS FPCT LEU-229 AND THR-324.
RX   PubMed=10477430;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:3<222::AID-HUMU5>3.0.CO;2-V;
RA   Christiansen L., Ged C., Hombrados I., Broens-Poulsen J.,
RA   Fontanellas A., de Verneuil H., Hoerder M., Petersen N.E.;
RT   "Screening for mutations in the uroporphyrinogen decarboxylase gene
RT   using denaturing gradient gel electrophoresis. Identification and
RT   characterization of six novel mutations associated with familial
RT   PCT.";
RL   Hum. Mutat. 14:222-232(1999).
RN   [33]
RP   VARIANTS FPCT SER-80; GLN-134; PRO-144; GLN-216; LYS-218; VAL-281;
RP   ARG-282; SER-303 AND ARG-318, AND CHARACTERIZATION OF VARIANTS FPCT
RP   PRO-144 AND LYS-218.
RX   PubMed=11069625; DOI=10.1046/j.1523-1747.2000.00148.x;
RA   Brady J.J., Jackson H.A., Roberts A.G., Morgan R.R., Whatley S.D.,
RA   Rowlands G.L., Darby C., Shudell E., Watson R., Paiker J.,
RA   Worwood M.W., Elder G.H.;
RT   "Co-inheritance of mutations in the uroporphyrinogen decarboxylase and
RT   hemochromatosis genes accelerates the onset of porphyria cutanea
RT   tarda.";
RL   J. Invest. Dermatol. 115:868-874(2000).
RN   [34]
RP   VARIANTS FPCT GLN-142; GLN-161; PHE-219 AND SER-235.
RX   PubMed=11295834; DOI=10.1002/humu.35;
RA   Cappellini M.D., Martinez Di Montemuros F., Tavazzi D., Fargion S.,
RA   Pizzuti A., Comino A., Cainelli T., Fiorelli G.;
RT   "Seven novel point mutations in the uroporphyrinogen decarboxylase
RT   (UROD) gene in patients with familial porphyria cutanea tarda (f-
RT   PCT).";
RL   Hum. Mutat. 17:350-350(2001).
RN   [35]
RP   VARIANT HEP LEU-46, AND CHARACTERIZATION OF VARIANT HEP LEU-46.
RX   PubMed=12071824; DOI=10.1001/archderm.138.7.957;
RA   Ged C., Ozalla D., Herrero C., Lecha M., Mendez M., de Verneuil H.,
RA   Mascaro J.M.;
RT   "Description of a new mutation in hepatoerythropoietic porphyria and
RT   prenatal exclusion of a homozygous fetus.";
RL   Arch. Dermatol. 138:957-960(2002).
RN   [36]
RP   VARIANT HEP LEU-46.
RX   PubMed=15491440; DOI=10.1111/j.1365-2133.2004.06101.x;
RA   Armstrong D.K.B., Sharpe P.C., Chambers C.R., Whatley S.D.,
RA   Roberts A.G., Elder G.H.;
RT   "Hepatoerythropoietic porphyria: a missense mutation in the UROD gene
RT   is associated with mild disease and an unusual porphyrin excretion
RT   pattern.";
RL   Br. J. Dermatol. 151:920-923(2004).
RN   [37]
RP   VARIANT HEP ARG-168, AND CHARACTERIZATION OF VARIANT HEP ARG-168.
RX   PubMed=17240319; DOI=10.1016/j.trsl.2006.08.006;
RA   Phillips J.D., Whitby F.G., Stadtmueller B.M., Edwards C.Q.,
RA   Hill C.P., Kushner J.P.;
RT   "Two novel uroporphyrinogen decarboxylase (URO-D) mutations causing
RT   hepatoerythropoietic porphyria (HEP).";
RL   Transl. Res. 149:85-91(2007).
RN   [38]
RP   VARIANT HEP ASP-170, AND CHARACTERIZATION OF VARIANT HEP ASP-170.
RX   PubMed=21668429; DOI=10.1111/j.1365-2133.2011.10453.x;
RA   To-Figueras J., Phillips J., Gonzalez-Lopez J.M., Badenas C.,
RA   Madrigal I., Gonzalez-Romaris E.M., Ramos C., Aguirre J.M.,
RA   Herrero C.;
RT   "Hepatoerythropoietic porphyria due to a novel mutation in the
RT   uroporphyrinogen decarboxylase gene.";
RL   Br. J. Dermatol. 165:499-505(2011).
CC   -!- FUNCTION: Catalyzes the decarboxylation of four acetate groups of
CC       uroporphyrinogen-III to yield coproporphyrinogen-III.
CC   -!- CATALYTIC ACTIVITY: Uroporphyrinogen III = coproporphyrinogen + 4
CC       CO(2).
CC   -!- PATHWAY: Porphyrin-containing compound metabolism; protoporphyrin-
CC       IX biosynthesis; coproporphyrinogen-III from 5-aminolevulinate:
CC       step 4/4.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:14633982,
CC       ECO:0000269|PubMed:9194196, ECO:0000269|PubMed:9564029}.
CC   -!- INTERACTION:
CC       Q96KN1:FAM84B; NbExp=5; IntAct=EBI-2871776, EBI-9057780;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- DISEASE: Familial porphyria cutanea tarda (FPCT) [MIM:176100]: A
CC       form of porphyria. Porphyrias are inherited defects in the
CC       biosynthesis of heme, resulting in the accumulation and increased
CC       excretion of porphyrins or porphyrin precursors. They are
CC       classified as erythropoietic or hepatic, depending on whether the
CC       enzyme deficiency occurs in red blood cells or in the liver.
CC       Familial porphyria cutanea tarda is an autosomal dominant disorder
CC       characterized by light-sensitive dermatitis, with onset in later
CC       life. It is associated with the excretion of large amounts of
CC       uroporphyrin in the urine. Iron overload is often present in
CC       association with varying degrees of liver damage.
CC       {ECO:0000269|PubMed:10338097, ECO:0000269|PubMed:10477430,
CC       ECO:0000269|PubMed:11069625, ECO:0000269|PubMed:11295834,
CC       ECO:0000269|PubMed:11719352, ECO:0000269|PubMed:2243121,
CC       ECO:0000269|PubMed:2920211, ECO:0000269|PubMed:7706766,
CC       ECO:0000269|PubMed:8896428, ECO:0000269|PubMed:9792863}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Hepatoerythropoietic porphyria (HEP) [MIM:176100]: A form
CC       of porphyria. Porphyrias are inherited defects in the biosynthesis
CC       of heme, resulting in the accumulation and increased excretion of
CC       porphyrins or porphyrin precursors. They are classified as
CC       erythropoietic or hepatic, depending on whether the enzyme
CC       deficiency occurs in red blood cells or in the liver. HEP is a
CC       cutaneous porphyria that presents in infancy. It is characterized
CC       biochemically by excessive excretion of acetate-substituted
CC       porphyrins and accumulation of protoporphyrin in erythrocytes.
CC       Uroporphyrinogen decarboxylase levels are very low in erythrocytes
CC       and cultured skin fibroblasts. {ECO:0000269|PubMed:12071824,
CC       ECO:0000269|PubMed:15491440, ECO:0000269|PubMed:1634232,
CC       ECO:0000269|PubMed:17240319, ECO:0000269|PubMed:1905636,
CC       ECO:0000269|PubMed:21668429, ECO:0000269|PubMed:3775362,
CC       ECO:0000269|PubMed:8176248, ECO:0000269|PubMed:8644733,
CC       ECO:0000269|PubMed:8896428}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the uroporphyrinogen decarboxylase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Uroporphyrinogen III
CC       decarboxylase entry;
CC       URL="https://en.wikipedia.org/wiki/Uroporphyrinogen_III_decarboxylase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14016; AAA61258.1; -; mRNA.
DR   EMBL; X89267; CAA61540.1; -; Genomic_DNA.
DR   EMBL; AF047383; AAC03563.1; -; Genomic_DNA.
DR   EMBL; AF104421; AAD04571.1; -; mRNA.
DR   EMBL; AF104422; AAD04572.1; -; mRNA.
DR   EMBL; AF104423; AAD04573.1; -; mRNA.
DR   EMBL; AF104424; AAD04574.1; -; mRNA.
DR   EMBL; AF104425; AAD04575.1; -; mRNA.
DR   EMBL; AF104426; AAD04576.1; -; mRNA.
DR   EMBL; AF104427; AAD04577.1; -; mRNA.
DR   EMBL; AF104428; AAD04578.1; -; mRNA.
DR   EMBL; AF104429; AAD04579.1; -; mRNA.
DR   EMBL; AF104430; AAD04580.1; -; mRNA.
DR   EMBL; AF104431; AAD04581.1; -; mRNA.
DR   EMBL; AF104432; AAD04582.1; -; mRNA.
DR   EMBL; AF104433; AAD04583.1; -; mRNA.
DR   EMBL; AF104434; AAD04584.1; -; mRNA.
DR   EMBL; AF104435; AAD04585.1; -; mRNA.
DR   EMBL; AF104436; AAD04586.1; -; mRNA.
DR   EMBL; AF104437; AAD04587.1; -; mRNA.
DR   EMBL; AF104438; AAD04588.1; -; mRNA.
DR   EMBL; AF104439; AAD04589.1; -; mRNA.
DR   EMBL; AF104440; AAD04590.1; -; mRNA.
DR   EMBL; AY292986; AAP44118.1; -; Genomic_DNA.
DR   EMBL; BT006737; AAP35383.1; -; mRNA.
DR   EMBL; CR456976; CAG33257.1; -; mRNA.
DR   EMBL; CR542057; CAG46854.1; -; mRNA.
DR   EMBL; AK291877; BAF84566.1; -; mRNA.
DR   EMBL; AL359473; CAI16440.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07007.1; -; Genomic_DNA.
DR   EMBL; BC001778; AAH01778.1; -; mRNA.
DR   EMBL; U30787; AAC50482.1; -; Genomic_DNA.
DR   EMBL; M60891; AAB59456.1; -; Genomic_DNA.
DR   CCDS; CCDS518.1; -.
DR   PIR; A24411; A24411.
DR   PIR; G02786; G02786.
DR   RefSeq; NP_000365.3; NM_000374.4.
DR   UniGene; Hs.78601; -.
DR   PDB; 1JPH; X-ray; 2.10 A; A=1-367.
DR   PDB; 1JPI; X-ray; 2.30 A; A=1-367.
DR   PDB; 1JPK; X-ray; 2.20 A; A=1-367.
DR   PDB; 1R3Q; X-ray; 1.70 A; A=1-367.
DR   PDB; 1R3R; X-ray; 1.85 A; A=1-367.
DR   PDB; 1R3S; X-ray; 1.65 A; A=1-367.
DR   PDB; 1R3T; X-ray; 1.70 A; A=1-367.
DR   PDB; 1R3V; X-ray; 1.90 A; A=1-367.
DR   PDB; 1R3W; X-ray; 1.70 A; A=1-367.
DR   PDB; 1R3Y; X-ray; 1.75 A; A=1-367.
DR   PDB; 1URO; X-ray; 1.80 A; A=1-367.
DR   PDB; 2Q6Z; X-ray; 2.00 A; A=11-366.
DR   PDB; 2Q71; X-ray; 1.90 A; A=11-366.
DR   PDB; 3GVQ; X-ray; 2.10 A; A=1-367.
DR   PDB; 3GVR; X-ray; 2.20 A; A=1-367.
DR   PDB; 3GVV; X-ray; 2.80 A; A=1-367.
DR   PDB; 3GVW; X-ray; 2.80 A; A=1-367.
DR   PDB; 3GW0; X-ray; 2.00 A; A=1-367.
DR   PDB; 3GW3; X-ray; 1.70 A; A=1-367.
DR   PDBsum; 1JPH; -.
DR   PDBsum; 1JPI; -.
DR   PDBsum; 1JPK; -.
DR   PDBsum; 1R3Q; -.
DR   PDBsum; 1R3R; -.
DR   PDBsum; 1R3S; -.
DR   PDBsum; 1R3T; -.
DR   PDBsum; 1R3V; -.
DR   PDBsum; 1R3W; -.
DR   PDBsum; 1R3Y; -.
DR   PDBsum; 1URO; -.
DR   PDBsum; 2Q6Z; -.
DR   PDBsum; 2Q71; -.
DR   PDBsum; 3GVQ; -.
DR   PDBsum; 3GVR; -.
DR   PDBsum; 3GVV; -.
DR   PDBsum; 3GVW; -.
DR   PDBsum; 3GW0; -.
DR   PDBsum; 3GW3; -.
DR   DisProt; DP00308; -.
DR   ProteinModelPortal; P06132; -.
DR   SMR; P06132; -.
DR   BioGrid; 113235; 19.
DR   IntAct; P06132; 11.
DR   MINT; MINT-3005024; -.
DR   STRING; 9606.ENSP00000246337; -.
DR   ChEMBL; CHEMBL1681619; -.
DR   DrugBank; DB03727; Coproporphyrin I.
DR   DrugBank; DB04461; Coproporphyrin Iii.
DR   iPTMnet; P06132; -.
DR   PhosphoSitePlus; P06132; -.
DR   BioMuta; UROD; -.
DR   DMDM; 2507533; -.
DR   OGP; P06132; -.
DR   EPD; P06132; -.
DR   MaxQB; P06132; -.
DR   PaxDb; P06132; -.
DR   PeptideAtlas; P06132; -.
DR   PRIDE; P06132; -.
DR   TopDownProteomics; P06132; -.
DR   DNASU; 7389; -.
DR   Ensembl; ENST00000246337; ENSP00000246337; ENSG00000126088.
DR   GeneID; 7389; -.
DR   KEGG; hsa:7389; -.
DR   UCSC; uc001cna.3; human.
DR   CTD; 7389; -.
DR   DisGeNET; 7389; -.
DR   GeneCards; UROD; -.
DR   GeneReviews; UROD; -.
DR   HGNC; HGNC:12591; UROD.
DR   HPA; HPA027468; -.
DR   HPA; HPA028668; -.
DR   HPA; HPA030350; -.
DR   MalaCards; UROD; -.
DR   MIM; 176100; phenotype.
DR   MIM; 613521; gene.
DR   neXtProt; NX_P06132; -.
DR   OpenTargets; ENSG00000126088; -.
DR   Orphanet; 95159; Hepatoerythropoietic porphyria.
DR   Orphanet; 101330; Porphyria cutanea tarda.
DR   PharmGKB; PA37221; -.
DR   eggNOG; KOG2872; Eukaryota.
DR   eggNOG; COG0407; LUCA.
DR   GeneTree; ENSGT00390000018302; -.
DR   HOVERGEN; HBG000229; -.
DR   InParanoid; P06132; -.
DR   KO; K01599; -.
DR   OMA; EHVPVWC; -.
DR   OrthoDB; EOG091G0EUA; -.
DR   PhylomeDB; P06132; -.
DR   TreeFam; TF300744; -.
DR   BioCyc; MetaCyc:HS04993-MONOMER; -.
DR   BRENDA; 4.1.1.37; 2681.
DR   Reactome; R-HSA-189451; Heme biosynthesis.
DR   UniPathway; UPA00251; UER00321.
DR   ChiTaRS; UROD; human.
DR   EvolutionaryTrace; P06132; -.
DR   GeneWiki; Uroporphyrinogen_III_decarboxylase; -.
DR   GenomeRNAi; 7389; -.
DR   PRO; PR:P06132; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000126088; -.
DR   CleanEx; HS_UROD; -.
DR   ExpressionAtlas; P06132; baseline and differential.
DR   Genevisible; P06132; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0004853; F:uroporphyrinogen decarboxylase activity; IDA:UniProtKB.
DR   GO; GO:0006783; P:heme biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006782; P:protoporphyrinogen IX biosynthetic process; IEA:UniProtKB-UniPathway.
DR   CDD; cd00717; URO-D; 1.
DR   HAMAP; MF_00218; URO_D; 1.
DR   InterPro; IPR006361; Uroporphyrinogen_deCO2ase_HemE.
DR   InterPro; IPR000257; Uroporphyrinogen_deCOase.
DR   Pfam; PF01208; URO-D; 1.
DR   TIGRFAMs; TIGR01464; hemE; 1.
DR   PROSITE; PS00906; UROD_1; 1.
DR   PROSITE; PS00907; UROD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm;
KW   Decarboxylase; Direct protein sequencing; Disease mutation;
KW   Heme biosynthesis; Lyase; Porphyrin biosynthesis; Reference proteome.
FT   CHAIN         1    367       Uroporphyrinogen decarboxylase.
FT                                /FTId=PRO_0000187569.
FT   REGION       37     41       Substrate binding.
FT   BINDING      55     55       Substrate.
FT   BINDING      85     85       Substrate.
FT   BINDING      86     86       Substrate.
FT   BINDING     164    164       Substrate.
FT   BINDING     219    219       Substrate.
FT   BINDING     339    339       Substrate.
FT   SITE         86     86       Transition state stabilizer.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   VARIANT      15     15       K -> E (in dbSNP:rs11541959).
FT                                /FTId=VAR_060683.
FT   VARIANT      25     25       G -> E (in FPCT; insoluble protein;
FT                                dbSNP:rs764268015).
FT                                {ECO:0000269|PubMed:11719352}.
FT                                /FTId=VAR_022567.
FT   VARIANT      46     46       F -> L (in HEP; mild phenotype; strong
FT                                decrease of activity; dbSNP:rs769378741).
FT                                {ECO:0000269|PubMed:12071824,
FT                                ECO:0000269|PubMed:15491440}.
FT                                /FTId=VAR_022568.
FT   VARIANT      62     62       P -> L (in HEP; dbSNP:rs121918060).
FT                                {ECO:0000269|PubMed:8644733}.
FT                                /FTId=VAR_009103.
FT   VARIANT      77     77       P -> L (in dbSNP:rs1131147).
FT                                {ECO:0000269|PubMed:8644733,
FT                                ECO:0000269|Ref.4, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_067457.
FT   VARIANT      80     80       A -> G (in HEP; dbSNP:rs776907084).
FT                                {ECO:0000269|PubMed:8896428}.
FT                                /FTId=VAR_007910.
FT   VARIANT      80     80       A -> S (in FPCT; decrease of activity;
FT                                dbSNP:rs376921379).
FT                                {ECO:0000269|PubMed:11069625,
FT                                ECO:0000269|PubMed:11719352}.
FT                                /FTId=VAR_022569.
FT   VARIANT     106    106       P -> L (in dbSNP:rs11541962).
FT                                /FTId=VAR_060684.
FT   VARIANT     113    113       R -> T (in dbSNP:rs11541963).
FT                                /FTId=VAR_060685.
FT   VARIANT     134    134       V -> Q (in FPCT and HEP; requires 2
FT                                nucleotide substitutions; nearly normal
FT                                activity). {ECO:0000269|PubMed:10338097,
FT                                ECO:0000269|PubMed:11069625,
FT                                ECO:0000269|PubMed:11719352,
FT                                ECO:0000269|PubMed:8176248}.
FT                                /FTId=VAR_009104.
FT   VARIANT     142    142       R -> Q (in FPCT).
FT                                {ECO:0000269|PubMed:11295834}.
FT                                /FTId=VAR_010985.
FT   VARIANT     144    144       R -> P (in FPCT; decrease of activity).
FT                                {ECO:0000269|PubMed:11069625}.
FT                                /FTId=VAR_022570.
FT   VARIANT     156    156       G -> D (in FPCT; decrease of activity;
FT                                dbSNP:rs762617943).
FT                                {ECO:0000269|PubMed:11719352}.
FT                                /FTId=VAR_022571.
FT   VARIANT     161    161       L -> Q (in FPCT).
FT                                {ECO:0000269|PubMed:11295834}.
FT                                /FTId=VAR_010986.
FT   VARIANT     165    165       M -> R (in FPCT; activity < 2%;
FT                                dbSNP:rs121918063).
FT                                {ECO:0000269|PubMed:11719352,
FT                                ECO:0000269|PubMed:9792863}.
FT                                /FTId=VAR_007911.
FT   VARIANT     167    167       E -> K (in HEP and FPCT; nearly normal
FT                                activity; dbSNP:rs121918058).
FT                                {ECO:0000269|PubMed:11719352,
FT                                ECO:0000269|PubMed:1905636}.
FT                                /FTId=VAR_007714.
FT   VARIANT     168    168       G -> R (in HEP; relative activity of 65%
FT                                of wild-type towards uroporphyrinogen
FT                                III). {ECO:0000269|PubMed:17240319}.
FT                                /FTId=VAR_065558.
FT   VARIANT     170    170       G -> D (in HEP; relative activity of 17%
FT                                and 60% of wild-type towards
FT                                uroporphyrinogen I and III respectively).
FT                                {ECO:0000269|PubMed:21668429}.
FT                                /FTId=VAR_065559.
FT   VARIANT     193    193       R -> P (in FPCT; insoluble protein).
FT                                {ECO:0000269|PubMed:11719352}.
FT                                /FTId=VAR_022572.
FT   VARIANT     195    195       L -> F (in FPCT; dbSNP:rs121918064).
FT                                {ECO:0000269|PubMed:9792863}.
FT                                /FTId=VAR_007912.
FT   VARIANT     216    216       L -> Q (in FPCT).
FT                                {ECO:0000269|PubMed:11069625}.
FT                                /FTId=VAR_022573.
FT   VARIANT     218    218       E -> K (in FPCT; significant decrease of
FT                                activity). {ECO:0000269|PubMed:11069625}.
FT                                /FTId=VAR_022574.
FT   VARIANT     219    219       S -> F (in FPCT).
FT                                {ECO:0000269|PubMed:11295834}.
FT                                /FTId=VAR_010987.
FT   VARIANT     220    220       H -> P (in HEP; mild form).
FT                                {ECO:0000269|PubMed:8176248}.
FT                                /FTId=VAR_009105.
FT   VARIANT     229    229       F -> L (in FPCT).
FT                                {ECO:0000269|PubMed:10477430}.
FT                                /FTId=VAR_009106.
FT   VARIANT     232    232       F -> L (in FPCT; decrease of activity).
FT                                {ECO:0000269|PubMed:11719352}.
FT                                /FTId=VAR_022575.
FT   VARIANT     235    235       P -> S (in FPCT; dbSNP:rs141312224).
FT                                {ECO:0000269|PubMed:11295834}.
FT                                /FTId=VAR_010988.
FT   VARIANT     253    253       L -> Q (in FPCT; decrease of activity;
FT                                dbSNP:rs36033115).
FT                                {ECO:0000269|PubMed:11719352,
FT                                ECO:0000269|PubMed:8896428}.
FT                                /FTId=VAR_007913.
FT   VARIANT     260    260       I -> T (in FPCT; decrease of activity).
FT                                {ECO:0000269|PubMed:11719352}.
FT                                /FTId=VAR_022576.
FT   VARIANT     281    281       G -> E (in FPCT and HEP;
FT                                dbSNP:rs121918057).
FT                                {ECO:0000269|PubMed:3775362,
FT                                ECO:0000269|PubMed:7706766,
FT                                ECO:0000269|PubMed:8644733}.
FT                                /FTId=VAR_007715.
FT   VARIANT     281    281       G -> V (in FPCT; dbSNP:rs121918057).
FT                                {ECO:0000269|PubMed:11069625,
FT                                ECO:0000269|PubMed:2920211}.
FT                                /FTId=VAR_007716.
FT   VARIANT     282    282       L -> R (in FPCT).
FT                                {ECO:0000269|PubMed:11069625}.
FT                                /FTId=VAR_022577.
FT   VARIANT     292    292       R -> G (in HEP; dbSNP:rs121918059).
FT                                {ECO:0000269|PubMed:1634232}.
FT                                /FTId=VAR_007717.
FT   VARIANT     303    303       G -> S (in FPCT).
FT                                {ECO:0000269|PubMed:11069625}.
FT                                /FTId=VAR_022578.
FT   VARIANT     303    303       G -> V (in dbSNP:rs17849533).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_060686.
FT   VARIANT     304    304       N -> K (in FPCT; dbSNP:rs121918065).
FT                                {ECO:0000269|PubMed:9792863}.
FT                                /FTId=VAR_007914.
FT   VARIANT     311    311       Y -> C (in HEP; dbSNP:rs121918061).
FT                                {ECO:0000269|PubMed:8644733}.
FT                                /FTId=VAR_009107.
FT   VARIANT     318    318       G -> R (in FPCT; dbSNP:rs116233118).
FT                                {ECO:0000269|PubMed:11069625,
FT                                ECO:0000269|PubMed:8896428}.
FT                                /FTId=VAR_007915.
FT   VARIANT     324    324       M -> T (in FPCT).
FT                                {ECO:0000269|PubMed:10477430}.
FT                                /FTId=VAR_009108.
FT   VARIANT     332    332       R -> H (in FPCT; dbSNP:rs121918066).
FT                                {ECO:0000269|PubMed:9792863}.
FT                                /FTId=VAR_007916.
FT   VARIANT     334    334       I -> T (in FPCT).
FT                                {ECO:0000269|PubMed:8896428}.
FT                                /FTId=VAR_007917.
FT   MUTAGEN      86     86       D->E: 5-10% of wild-type activity.
FT                                {ECO:0000269|PubMed:14633982}.
FT   MUTAGEN      86     86       D->G: Very low activity. Binds substrate
FT                                with similar geometry as wild-type.
FT                                {ECO:0000269|PubMed:14633982}.
FT   MUTAGEN      86     86       D->N: No activity. Unable to bind
FT                                substrate. {ECO:0000269|PubMed:14633982}.
FT   MUTAGEN     164    164       Y->F: 25-30% of wild-type activity.
FT                                {ECO:0000269|PubMed:14633982}.
FT   CONFLICT    103    103       G -> S (in Ref. 1; AAA61258 and 14;
FT                                AAB59456). {ECO:0000305}.
FT   CONFLICT    120    120       R -> A (in Ref. 1; AAA61258 and 14;
FT                                AAB59456). {ECO:0000305}.
FT   CONFLICT    212    214       Missing (in Ref. 14; AAB59456).
FT                                {ECO:0000305}.
FT   HELIX        18     24       {ECO:0000244|PDB:1R3S}.
FT   STRAND       38     40       {ECO:0000244|PDB:1R3S}.
FT   HELIX        44     51       {ECO:0000244|PDB:1R3S}.
FT   HELIX        55     59       {ECO:0000244|PDB:1R3S}.
FT   HELIX        62     75       {ECO:0000244|PDB:1R3S}.
FT   HELIX        89     93       {ECO:0000244|PDB:1R3S}.
FT   STRAND       99    101       {ECO:0000244|PDB:1R3S}.
FT   TURN        102    104       {ECO:0000244|PDB:1R3S}.
FT   STRAND      105    107       {ECO:0000244|PDB:1R3S}.
FT   HELIX       115    120       {ECO:0000244|PDB:1R3S}.
FT   HELIX       124    126       {ECO:0000244|PDB:1R3S}.
FT   HELIX       127    130       {ECO:0000244|PDB:1R3S}.
FT   HELIX       132    145       {ECO:0000244|PDB:1R3S}.
FT   STRAND      151    156       {ECO:0000244|PDB:1R3S}.
FT   HELIX       158    167       {ECO:0000244|PDB:1R3S}.
FT   HELIX       175    183       {ECO:0000244|PDB:1R3S}.
FT   HELIX       185    208       {ECO:0000244|PDB:1R3S}.
FT   STRAND      212    218       {ECO:0000244|PDB:1R3S}.
FT   HELIX       221    223       {ECO:0000244|PDB:1R3S}.
FT   HELIX       226    232       {ECO:0000244|PDB:1R3S}.
FT   HELIX       234    250       {ECO:0000244|PDB:1R3S}.
FT   STRAND      258    262       {ECO:0000244|PDB:1R3S}.
FT   HELIX       266    268       {ECO:0000244|PDB:1R3S}.
FT   HELIX       269    272       {ECO:0000244|PDB:1R3S}.
FT   TURN        273    276       {ECO:0000244|PDB:3GVV}.
FT   STRAND      278    281       {ECO:0000244|PDB:1R3S}.
FT   HELIX       288    295       {ECO:0000244|PDB:1R3S}.
FT   STRAND      297    305       {ECO:0000244|PDB:1R3S}.
FT   HELIX       307    311       {ECO:0000244|PDB:1R3S}.
FT   HELIX       314    328       {ECO:0000244|PDB:1R3S}.
FT   STRAND      330    339       {ECO:0000244|PDB:1R3S}.
FT   HELIX       347    365       {ECO:0000244|PDB:1R3S}.
SQ   SEQUENCE   367 AA;  40787 MW;  840510B36CFC3856 CRC64;
     MEANGLGPQG FPELKNDTFL RAAWGEETDY TPVWCMRQAG RYLPEFRETR AAQDFFSTCR
     SPEACCELTL QPLRRFPLDA AIIFSDILVV PQALGMEVTM VPGKGPSFPE PLREEQDLER
     LRDPEVVASE LGYVFQAITL TRQRLAGRVP LIGFAGAPWT LMTYMVEGGG SSTMAQAKRW
     LYQRPQASHQ LLRILTDALV PYLVGQVVAG AQALQLFESH AGHLGPQLFN KFALPYIRDV
     AKQVKARLRE AGLAPVPMII FAKDGHFALE ELAQAGYEVV GLDWTVAPKK ARECVGKTVT
     LQGNLDPCAL YASEEEIGQL VKQMLDDFGP HRYIANLGHG LYPDMDPEHV GAFVDAVHKH
     SRLLRQN
//
